Vasoactive mediators of hypertension in obesity

被引:2
作者
Ghanim, Husam [1 ]
Thethi, Tina K. [2 ]
Abuaysheh, Sanaa [1 ]
Fonseca, Vivian [3 ]
Dandona, Paresh [1 ]
机构
[1] SUNY Buffalo, Jacobs Sch Med & Biomed Sci, Dept Med, Div Endocrinol Diabet & Metab, Buffalo, NY 14222 USA
[2] AdventHlth, Translat Res Inst, Orlando, FL USA
[3] Tulane Univ, Hlth Sci Ctr, Tulane Med Ctr, New Orleans, LA USA
来源
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM | 2023年 / 325卷 / 04期
基金
美国国家卫生研究院;
关键词
blood pressure; hypertension; obesity; BLOOD-PRESSURE;
D O I
10.1152/ajpendo.00209.2022
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Obesity is associated with hypertension. However, the mechanisms involved are not fully understood. Therefore, we investigated the relationship between obesity and vasoactive mediators. In this cross-sectional study, blood pressure (BP) and vasoactive mediators of hypertension are compared among 135 adults in the nonobese, obese, and morbidly obese body mass index (BMI) ranges (BMI <= 27, 30-40, and >40 kg/m(2), respectively). Angiotensinogen, angiotensin II, renin, aldosterone, endothelin-1 (ET-1), neprilysin, atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), cyclic guanosine monophosphate (cGMP), and cyclic adenosine monophosphate (cAMP) levels were measured and their relationship to BP, BMI, race, and gender were investigated. Systolic and diastolic BP (SBP and DSP) were significantly higher in subjects with obesity and morbid obesity compared with nonobese. Angiotensin II, ET-1, and neprilysin were significantly higher in subjects with morbid obesity while BNP was lower. Levels of angiotensinogen, renin, aldosterone, ANP, cGMP, and cAMP did not differ between the groups. BMI was positively related to SBP, DBP, angiotensin II, ET-1, and neprilysin, and inversely related to cGMP and BNP. Age, male gender, and African-American race were associated with higher SBP. SBP was positively related to angiotensin II and ET-1 and inversely related to aldosterone, renin, and cGMP. On multivariate analyses, age, BMI, gender, and race were the main determinants of SBP, and excluding these variables, angiotensin II, aldosterone, renin, and ET-1 accounted for 21.1% ability to predict SBP. Obesity, especially morbid obesity, is associated with higher BP, higher angiotensin II and ET-1 (vasoconstrictors), and lower levels BNP and cGMP (vasodilators). SBP variability can be partly explained by angiotensin II, aldosterone, renin, and ET-1.
引用
收藏
页码:E406 / E411
页数:6
相关论文
共 15 条
  • [1] [Anonymous], 2005, AM J MANAG CARE, V11, pS383
  • [2] Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption
    Azizi, M
    Ménard, J
    Bissery, A
    Guyenne, TT
    Bura-Rivière, A
    Vaidyanathan, S
    Camisasca, RP
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (12): : 3126 - 3133
  • [3] Exenatide induces an increase in vasodilatory and a decrease in vasoconstrictive mediators
    Chaudhuri, Ajay
    Ghanim, Husam
    Makdissi, Antoine
    Green, Kelly
    Abuaysheh, Sanaa
    Batra, Manav
    Kuhadiya, Nitesh D.
    Dandona, Paresh
    [J]. DIABETES OBESITY & METABOLISM, 2017, 19 (05) : 729 - 733
  • [4] Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: Insights from a patient-level pooled analysis of six randomized clinical trials
    Fonseca, Vivian A.
    DeVries, J. Hans
    Henry, Robert R.
    Donsmark, Morten
    Thomsen, Henrik F.
    Plutzky, Jorge
    [J]. JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2014, 28 (03) : 399 - 405
  • [5] Ford Cassandra D, 2014, J Health Dispar Res Pract, V7, P32
  • [6] Dapagliflozin reduces systolic blood pressure and modulates vasoactive factors
    Ghanim, Husam
    Batra, Manav
    Green, Kelly
    Hejna, Jeanne
    Abuaysheh, Sanaa
    Makdissi, Antione
    Chaudhuri, Ajay
    Dandona, Paresh
    [J]. DIABETES OBESITY & METABOLISM, 2021, 23 (07) : 1614 - 1623
  • [7] Decreases in neprilysin and vasoconstrictors and increases in vasodilators following bariatric surgery
    Ghanim, Husam
    Monte, Scott
    Caruana, Joseph
    Green, Kelly
    Abuaysheh, Sanaa
    Dandona, Paresh
    [J]. DIABETES OBESITY & METABOLISM, 2018, 20 (08) : 2029 - 2033
  • [8] Control of Renin Synthesis and Secretion
    Kurtz, Armin
    [J]. AMERICAN JOURNAL OF HYPERTENSION, 2012, 25 (08) : 839 - 847
  • [9] Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure
    McMurray, John J. V.
    Packer, Milton
    Desai, Akshay S.
    Gong, Jianjian
    Lefkowitz, Martin P.
    Rizkala, Adel R.
    Rouleau, Jean L.
    Shi, Victor C.
    Solomon, Scott D.
    Swedberg, Karl
    Zile, Michael R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (11) : 993 - 1004
  • [10] Race and diurnal blood pressure patterns - A review and meta-analysis
    Profant, J
    Dimsdale, JE
    [J]. HYPERTENSION, 1999, 33 (05) : 1099 - 1104